ConMed Beamer Study

Status Completed

Clinical Trial Summary

This is a prospective registry of all patients who endoscopic submucosal dissection (ESD), per-oral endoscopic myotomy (POEM) and gastric per-oral endoscopic myotomy (G-POEM) using ConMed Electrosurgical unit for submucosal Dissection at Baylor St Luke's Medical Center. Collected information includes; procedure technical success rate, duration, periprocedural complications and ease of use.

Clinical Trial Description

Submucosal endoscopy is a novel subset of procedures which enables endoscopist to utilize the submucosal space to perform advanced endoscopic procedures. The submucosa is the third layer of the gastrointestinal wall and it is a potential space which is expandable upon injecting the submucosa with fluid. The expanded submucosa causes a significant lift which enable dissection of the submucosal space with the removal of the overlying polyp or early cancer. The submucosal space can be also utilized to create a longitudinal submucosal tunnel in the esophagus or the stomach wall which allows for performing lower esophageal sphincter or pyloric myotomy for the treatment of achalasia or Gastroparesis. Currently, the most commonly performed submucosal endoscopy procedures are endoscopic submucosal dissection (ESD) for removal of early cancers or polyps throughout the gastrointestinal tract, Per-oral Endoscopic Myotomy (POEM) for treatment of achalasia, or Gastric Per-Oral Endoscopic myotomy for the treatment of Gastroparesis. All of the above procedures require a specialized electrosurgical unit (ESU) which generate high frequency current to help incision (cutting) of the mucosa and dissection (coagulation) of the submucosa. The ConMed Beamer is a novel ESU with tissue sensing property which expedites the process of submucosal dissection. The device is currently approved for clinical use in the US. The purpose of this study is to create registry for all submucosal endoscopy procedures performed using ConMed Beamer device at BSLMC with focus on clinical outcomes of the procedure including adverse events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04752670
Study type	Observational [Patient Registry]
Source	Baylor College of Medicine
Contact
Status	Completed
Phase
Start date	May 27, 2021
Completion date	May 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03941288` - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia	Phase 2
Terminated	`NCT03285308` - A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01	Phase 3
Completed	`NCT00733551` - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.	Phase 1
Completed	`NCT01650714` - Endoscopic Full Thickness Biopsy, Gastric Wall.	N/A
Completed	`NCT01452815` - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis	Phase 2
Completed	`NCT01039974` - GSK962040 Drug-drug Interaction Study With Ketoconazole	Phase 1
Terminated	`NCT04844190` - Use of EndoFLIP and Manometry Prior to G-POEM	N/A
Enrolling by invitation	`NCT06215547` - Medtronic Enterra II Neurostimulator	N/A
Completed	`NCT04026997` - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis	Phase 2
Completed	`NCT00562848` - A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040	Phase 1
Enrolling by invitation	`NCT04207996` - Vagus Nerve Response in Gastroparesis Patients
Completed	`NCT04607304` - ABCA2 GIRMS Analytical Validation Clinical Performance Study	N/A
Recruiting	`NCT06068114` - Gastric Pathophysiology in Diabetes
Completed	`NCT03259841` - Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
Active, not recruiting	`NCT04300127` - Pioglitazone for Idiopathic Gastroparesis	Early Phase 1
Recruiting	`NCT01696734` - Domperidone in Treating Patients With Gastrointestinal Disorders	Phase 3
Terminated	`NCT04635306` - 13C-Spirulina Nitrogen Content GEBT Study	N/A
Withdrawn	`NCT02420925` - Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis	N/A
Recruiting	`NCT00777439` - Domperidone for Refractory Gastrointestinal Disorders	N/A
Terminated	`NCT00760461` - Domperidone in Refractory Gastroparesis	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.